Analyst Research

Report Title Price
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Pechala's Reports
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Novo Nordisk A/S says diabetes drug appears effective for weight loss


Saturday, 14 Jun 2014 11:30am EDT 

Novo Nordisk A/S:Says its diabetes drug Victoza appears to be an effective weight loss therapy, as demonstrated by data from a late-stage clinical trial presented on June 14.In the 56-week study of 846 overweight or obese adults with type 2 diabetes, a daily injection of 3 milligrams of Victoza led to significantly greater weight loss than did a placebo.Patients taking the 3 mg dose of the drug, known chemically as liraglutide, had a mean loss of 5.9 percent of body weight.That compared with a loss of 4.6 percent for a 1.8 mg dose and just 2 percent loss for those who got a placebo.All patients were also put on a diet and exercise program.The results were presented at the American Diabetes Association meeting in San Francisco. 

Company Quote

45.41
-0.28 -0.61%
21 Aug 2014